Novel Mutation in Cytochrome B of Plasmodium falciparum in One of Two Atovaquone-Proguanil Treatment Failures in Travelers Returning From Same Site in Nigeria
Open Access
- 5 August 2014
- journal article
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 1 (2), ofu059
- https://doi.org/10.1093/ofid/ofu059
Abstract
Background. Atovaquone-proguanil (AP) is the most commonly used treatment for uncomplicated Plasmodium falciparum malaria in the United States. Apparent AP treatment failures were reported 7 months apart in 2 American travelers who stayed in the same compound for foreign workers in Rivers State, Nigeria. Methods. We analyzed pretreatment (day 0) and day of failure samples from both travelers for mutations in the P falciparum cytochrome B (pfcytb) and dihydrofolate reductase (pfdhfr) genes associated with resistance to atovaquone and cycloguanil, the active metabolite of proguanil, respectively. We genotyped the parasites and sequenced their mitochondrial genomes. Results. On day 0, both travelers had proguanil-resistant genotypes but atovaquone-sensitive cytb sequences. Day of failure samples exhibited mutations in cytb for both travelers. One traveler had the common Y268S mutation, whereas the other traveler had a previously unreported mutation, I258M. The travelers had unrelated parasite genotypes and different mitochondrial genomes. Conclusions. Despite the infections likely having been contracted in the same site, there is no evidence that the cases were related. The mutations likely arose independently during the acute infection or treatment. Our results highlight the importance of genotyping parasites and sequencing the full cytb and dhfr genes in AP failures to rule out transmission of AP-resistant strains and identify novel mechanisms of AP resistance.Keywords
This publication has 42 references indexed in Scilit:
- Atovaquone-proguanil in the treatment of imported uncomplicated Plasmodium falciparum malaria: a prospective observational study of 553 casesMalaria Journal, 2013
- Multiple genetic origins of histidine-rich protein 2 gene deletion in Plasmodium falciparum parasites from PeruScientific Reports, 2013
- Therapy of uncomplicated falciparum malaria in Europe: MALTHER – a prospective observational multicentre studyMalaria Journal, 2012
- Early treatment failure during treatment of Plasmodium falciparum malaria with atovaquone-proguanil in the Republic of Ivory CoastMalaria Journal, 2012
- Cytochrome b Mutation Y268S Conferring Atovaquone Resistance Phenotype in Malaria Parasite Results in Reduced Parasite bc1 Catalytic Turnover and Protein Expression*Published by Elsevier BV ,2012
- Costs analysis of the treatment of imported malariaMalaria Journal, 2012
- Mutations in the Plasmodium falciparum cytochrome b gene are associated with delayed parasite recrudescence in malaria patients treated with atovaquone-proguanilMalaria Journal, 2008
- First Case of Emergence of Atovaquone-Proguanil Resistance in Plasmodium falciparum during Treatment in a Traveler in ComorosAntimicrobial Agents and Chemotherapy, 2008
- Sequence analysis of Plasmodium falciparum cytochrome b in multiple geographic sitesMalaria Journal, 2007
- Common Origin and Fixation of Plasmodium falciparum dhfr and dhps Mutations Associated with Sulfadoxine-Pyrimethamine Resistance in a Low-Transmission Area in South AmericaAntimicrobial Agents and Chemotherapy, 2007